Company

SyneuRx International

Headquarters: New Taipei City, Taiwan

TWSE: 6575

Market Cap

TW$2.11 Billion

TWD as of Jan. 1, 2024

US$68.8 Million

Market Cap History

SyneuRx International market capitalization over time

Evolution of SyneuRx International market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of SyneuRx International

Detailed Description

SyneuRx International (Taiwan) Corp. develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan. Its pipeline under clinical development includes SND11, which is in Phase IIb/III clinical trial for the treatment of adolescent schizophrenia; SND12 that is in Phase IIb/III clinical trial for therapy on refractory schizophrenia; and SND13, which is in Phase IIb/III clinical trial for the treatment of adult schizophrenia. The company is also developing SND14, which is in Phase IIb/III clinical trial to treat early dementia; SND51 that is in Phase II clinical trial for dementia and psychosis symptoms; SNG12, which is in Phase III clinical trial for the treatment of depression and suicidality; SNA1 that is in Phase II clinical trial to treat refractory depression; and SNB01, which is in Phase II clinical trial for the treatment of COVID-19. SyneuRx International (Taiwan) Corp. was founded in 2013 and is based in New Taipei City, Taiwan.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

SyneuRx International has the following listings and related stock indices.


Stock: TWSE: 6575 wb_incandescent

Details

Headquarters:

No. 99, Xintai 5th Road

20th Floor-10 Sec. 1 Xizhi District

New Taipei City, 221

Taiwan

Phone: 886 2 7742 2699

Fax: 886 2 2697 2629